Vision Institute

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics

Retrieved on: 
Wednesday, July 12, 2023
Clinical trial, Retina, AAV, Doctor of Philosophy, IVT, Acquisition, GIRK, Patient, Vision Institute, GCT, Therapy, Visual acuity, IND, Pharmaceutical industry

SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach clinical stage in 2024

Key Points: 
  • SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach clinical stage in 2024
    Paris, July 12, 2023 – SparingVision (“the Company”), a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, today announces that it has sold its ex vivo GIRK1 technology to Tenpoint Therapeutics (“Tenpoint”).
  • SparingVision obtained its GIRK technology in April 2021 through the acquisition of GAMUT Therapeutics (“GAMUT”), which had developed a portfolio of products around GIRK to restore visual function in dormant cones.
  • Under the terms of the agreement, Tenpoint has acquired GCT gaining exclusive clinical and commercial rights to the ex vivo application of the GIRK technology.
  • Stéphane Boissel, President and Chief Executive Officer of SparingVision, said: “We believe that the GIRK technology has tremendous potential and this transaction with Tenpoint will help advance the development of the ex vivo GIRK technology as we remain wholly focused on our in vivo strategy.

Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming

Retrieved on: 
Wednesday, July 12, 2023
Biotechnology, Health, Science, Research, Optical, University, Therapy, AMD, Sofinnova, Eye, Paratriathlon, Cell, Doctor of Philosophy, ARCH Venture Partners, Regenerative medicine, Moorfields Eye Hospital, Patient, University of Washington Department of Bioengineering, Vision Institute, Capital, FDA, Patient capital, Pharmaceutical industry, Management, Ophthalmology, MD

F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.

Key Points: 
  • F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.
  • Based on these foundational achievements, Tenpoint is advancing approaches to generate specialized ocular cell types both ex vivo and in vivo.
  • “Cell-based therapeutics represent an ideal modality for degenerative ocular diseases since most vision loss results from damaged or missing tissue.
  • Vanessa King, PhD, Tenpoint’s founding CEO, led this financing of the company and will continue to support the organization as a strategic advisor.

Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024

Retrieved on: 
Thursday, December 15, 2022
Diamond, Primavera, Physician, AMF, Geographic atrophy, Mnemos EP, Vance DeGeneres, AMD, Rehabilitation, LogMAR chart, IMO, CET, Safety, PRIMA, EN, Moorfields Eye Hospital, Vision Institute, Visual acuity, Stanford University, Risk, Peripheral vision, University of Pittsburgh School of Medicine, Research, Wilfrid Sellars, University, Retinal degeneration, Patient, Prima, UPMC, Medical device, Medical imaging, Pharmaceutical industry

A total of 38 patients have been implanted with the Prima System in the PRIMAvera study (NCT04676854), an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial.

Key Points: 
  • A total of 38 patients have been implanted with the Prima System in the PRIMAvera study (NCT04676854), an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial.
  • The study is being conducted in leading clinical centers in France, Germany, the UK, the Netherlands, and Italy.
  • A read-out of the PRIMAvera study's primary endpoints is expected around the end of 2023.
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.

Pixium Vision announces participation in investor conferences in November and December 2022

Retrieved on: 
Tuesday, November 15, 2022
Diamond, OIS, UPMC, Carousel, University, EN, Mnemos EP, Showcase, La Salle, Patient, IMO, Rehabilitation, CET, Risk, LSX, Research, Retinal degeneration, Vision Institute, Vance DeGeneres, Stanford University, Moorfields Eye Hospital, AMF, Financial services, Management

Lloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer, will attend in person and host investor meetings.

Key Points: 
  • Lloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer, will attend in person and host investor meetings.
  • Pixium Vision management team members will be present at booth number 112 demonstrating the Prima System.
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.
  • Pixium Visions bionic vision systems are associated with a surgical intervention and a rehabilitation period.

Wellish Vision Institute Announces Expansion in Southwest Las Vegas

Retrieved on: 
Thursday, November 24, 2022
LAS, University of Pittsburgh Medical Center, Glaucoma, University, University at Buffalo, Patient, Vision Institute, UCLA, UCL Ear Institute, Ophthalmology, National Institutes of Health Clinical Center, Tran, Moses Austin, Morale, Cornea, Children's Mercy Hospital, University of California, Davis, University of Kansas Medical Center, Cataract, Retina, Duane syndrome, University of Arizona, Business administration, Massachusetts Eye and Ear, Apache, Optometry, Buffalo, University of Texas Southwestern Medical Center, GVHD, University of Washington Department of Global Health, Fort Apache, Harvard University, Master of Business Administration, Hotel, Veterinary medicine, Medical device, Seattle metropolitan area

LAS VEGAS, Nov. 23, 2022 /PRNewswire-PRWeb/ -- Wellish Vision Institute is excited to announce they are expanding into Southwest Las Vegas to better serve patients living in this area of Las Vegas. The practice is located at 6710 South Apache Road. The new practice boasts 7,200 square feet and includes 14 exam rooms, all equipped with same state-of-the-art technology found at the other three Wellish Vision locations.

Key Points: 
  • Wellish Vision Institute is excited to announce they are expanding into Southwest Las Vegas to better serve patients living in this area of Las Vegas.
  • LAS VEGAS, Nov. 23, 2022 /PRNewswire-PRWeb/ -- Wellish Vision Institute is excited to announce they are expanding into Southwest Las Vegas to better serve patients living in this area of Las Vegas.
  • As part of this expansion, Wellish Vision Institute is also excited to announce well-respected ophthalmologist Dr. Andrew Tran and optometrist Dr. Tiffany Nguyen are joining the highly trained eye care team at Wellish Vision.
  • Wellish Vision Institute is one of the leading ophthalmology practices in Las Vegas.

Pixium Vision announces the publication of peer-reviewed clinical data of the Prima System in Dry AMD in the Journal of Neural Engineering

Retrieved on: 
Tuesday, October 11, 2022
Diamond, Inner nuclear layer, EN, AMF, CET, Retinal degeneration, Geographic atrophy, Neural engineering, PRIMA, Total, Vance DeGeneres, Moorfields Eye Hospital, Primavera, Retina, Research, Mnemos EP, Optical coherence tomography, Risk, Institute, Nervous system, University, Company, INL, Vision Institute, Rehabilitation, Safety, Journal, IMO, UPMC, Stanford University, AMD, Medical device, Patient

Previously, the data from the French feasibility study already demonstrated that the Prima System is well tolerated.

Key Points: 
  • Previously, the data from the French feasibility study already demonstrated that the Prima System is well tolerated.
  • The data in this paper now further demonstrate the stability and minimal impact of the implant once in position.
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.
  • Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD).

Pixium Vision announces participation in investor conferences and events in October 2022

Retrieved on: 
Tuesday, October 4, 2022
Diamond, Vance DeGeneres, AMF, Rehabilitation, Stanford University, Moorfields Eye Hospital, Risk, Retinal degeneration, Research, UPMC, IMO, Vision Institute, Mnemos EP, Institute, Patient, CET, University, Company, EN, Management

Lloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer will attend in person.

Key Points: 
  • Lloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer will attend in person.
  • Lloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer will attend in person.
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.
  • Pixium Visions bionic vision systems are associated with a surgical intervention and a rehabilitation period.

Pixium Vision to host open house event for investors on October 13th 2022 from 5 pm

Retrieved on: 
Wednesday, September 21, 2022
Diamond, Institute, Risk, Retinal degeneration, Safety, UPMC, Company, Mnemos EP, Moorfields Eye Hospital, Primavera, IMO, Patient, Ownership, Technology, Vance DeGeneres, Vision Institute, Prima, EN, CET, Stanford University, Research, AMF, AMD, Virtual reality, Rehabilitation, University, Pharmaceutical industry, Medical device

Paris, France, September 21, 2022 07:00 CET Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today it will host an open house event for investors on Thursday, October 13th, 2022.

Key Points: 
  • Paris, France, September 21, 2022 07:00 CET Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today it will host an open house event for investors on Thursday, October 13th, 2022.
  • There will be a guided visit to the Pixium Vision laboratories including a technology demonstration.
  • The event will conclude with a drinks reception giving an opportunity to talk directly with the Pixium Vision team and use virtual reality to better apprehend the Prima system.
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.

Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022

Retrieved on: 
Monday, September 19, 2022
Institute, Risk, Retinal degeneration, Safety, Vision, UPMC, Company, Mnemos EP, Moorfields Eye Hospital, Primavera, LogMAR chart, IMO, Patient, Vance DeGeneres, Visual acuity, Vision Institute, Geographic atrophy, EN, CET, Stanford University, Research, AMF, AMD, Rehabilitation, University, Medical device, Pharmaceutical industry

A total of 38 patients have been enrolled in the PRIMAvera study (NCT04676854), an open-label, baseline-controlled, non-randomized, multi-center, prospective single-arm pivotal trial.

Key Points: 
  • A total of 38 patients have been enrolled in the PRIMAvera study (NCT04676854), an open-label, baseline-controlled, non-randomized, multi-center, prospective single-arm pivotal trial.
  • The study was initiated in Q4 2020 in France, where the first patient was enrolled in December 2020.
  • Pixium Vision has since established additional clinical sites and implanted patients in France, Germany, the UK, the Netherlands, and Italy.
  • Implantations are due to be completed by the end of 2022, and a read-out of the PRIMAvera study's primary endpoints is expected around the end of 2023.

Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera

Retrieved on: 
Tuesday, September 13, 2022
Institute, Risk, Retinal degeneration, Safety, UPMC, PRIMA, Hope, Company, Mnemos EP, Moorfields Eye Hospital, Primavera, LogMAR chart, IMO, Patient, Visual acuity, Vance DeGeneres, Vision Institute, EN, CET, Stanford University, Research, AMF, AMD, Rehabilitation, University, Disease, Dentistry, Medical device, Medical imaging, Health

The PRIMAvera study aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe.

Key Points: 
  • The PRIMAvera study aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe.
  • Pixium Vision has since established additional clinical sites and implanted patients in Germany, the UK and the Netherlands.
  • "We are very pleased to have successfully implanted the first patient in Italy with the Prima System as part of the expanding PRIMAvera pivotal study," said Prof. Andrea Cusumano, co-investigator of the PRIMAvera study for Italy.
  • A total of 38 patients will be implanted in the PRIMAvera study, an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial.